Skip to main content
OpenTrials
Completed

NCT Number: NCT04435223

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis. The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Severe Pneumonia Severe Pneumonia Due to Other Pathogene

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Dijon Bourgogne

Dijon, 21000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 2 of the following criteria: Cough/ Dyspnea/ Spitting/ Thoracic pain/ Hyperthermia (>=38 °C) Hypothermia (< 35°C) AND new radiologic pulmonary infiltrate
  • At admission or within 48 hours following hospital admission
  • With 2 qSOFA criteria: MAP =< 100 mmHg, Respiratory Rate >= 22, Glasgow score < 15 OR on mechanical ventilation OR under vasopressor
  • Age > 18
  • affiliated to social security

Exclusion criteria

  • Pregnancy
  • immunodepression
  • Pathology known to cause severe lymphopenia
  • hospitalisation within 3 month before inclusion AND sepsis

Treatment and study plan

biological assays in particular on the lipid metabolism

Biological

bioassays carried out on samples already collected and conserved

Primary outcomes

  1. Cholesterol concentration

    Time frame: Within 48 hours following hospital admission

Secondary outcomes

  1. LDL cholesterol / HDL cholesterol/ Lipoprotein size and composition/ Non esterified Fatty acid/ Triglyceridemia/ CETP and PLTP activity/ apolipoprotein canceration/ lipid peroxidation/ Pro and anti inflammatory profile.

    Time frame: Within 48 hours following hospital admission

    Ventilator free days (28 days)

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Acronym: COVIDOLIP

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jun 17, 2020
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.